Published in Sci Rep on March 11, 2015
Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells. Stem Cell Res Ther (2015) 0.86
Choosing the right cell line for renal cell cancer research. Mol Cancer (2016) 0.82
MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma. Cancer Med (2016) 0.79
Novel variants in MLL confer to bladder cancer recurrence identified by whole-exome sequencing. Oncotarget (2016) 0.77
Functional significance of CD105-positive cells in papillary renal cell carcinoma. BMC Cancer (2017) 0.77
Gigantol Suppresses Cancer Stem Cell-Like Phenotypes in Lung Cancer Cells. Evid Based Complement Alternat Med (2015) 0.77
Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells. Front Pharmacol (2016) 0.75
miR-150 Suppresses the Proliferation and Tumorigenicity of Leukemia Stem Cells by Targeting the Nanog Signaling Pathway. Front Pharmacol (2016) 0.75
STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma. Oncotarget (2016) 0.75
Growth-induced stress enhances epithelial-mesenchymal transition induced by IL-6 in clear cell renal cell carcinoma via the Akt/GSK-3β/β-catenin signaling pathway. Oncogenesis (2017) 0.75
Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol (2010) 24.32
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60
Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell (2013) 13.43
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 11.16
Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell (2002) 10.34
PI3K pathway alterations in cancer: variations on a theme. Oncogene (2008) 9.94
Renal cell carcinoma. Lancet (2009) 6.92
The cancer stem cell: premises, promises and challenges. Nat Med (2011) 6.73
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science (2007) 6.01
Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A (2004) 5.32
PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 4.81
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res (2001) 4.63
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell (2009) 4.47
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A (2007) 4.05
Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet (2011) 3.66
The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res (2003) 3.58
The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A (2008) 3.13
Unravelling cancer stem cell potential. Nat Rev Cancer (2013) 3.06
Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors. J Urol (2009) 2.43
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res (2011) 2.19
SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature (2014) 2.15
Control of actin filament treadmilling in cell motility. Annu Rev Biophys (2010) 2.15
Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins? Cancers (Basel) (2011) 2.10
PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res (2011) 1.91
The evolving concept of cancer and metastasis stem cells. J Cell Biol (2012) 1.76
PKB/Akt-dependent regulation of cell motility. J Natl Cancer Inst (2013) 1.41
The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. Cancer Res (2010) 1.41
The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer. Cell Cycle (2005) 1.39
Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk. Clin Cancer Res (2008) 1.31
PI3 kinase/Akt signaling mediates epithelial-mesenchymal transition in hypoxic hepatocellular carcinoma cells. Biochem Biophys Res Commun (2009) 1.29
Cancer stem cell biology: from leukemia to solid tumors. Curr Opin Cell Biol (2004) 1.27
Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene (2010) 1.23
PDGF signalling controls the migration of mesoderm cells during chick gastrulation by regulating N-cadherin expression. Development (2008) 1.21
Current management of advanced and metastatic renal cell carcinoma. Urol J (2010) 1.20
N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties. Oncogene (2013) 1.07
Epigenetic alterations involved in cancer stem cell reprogramming. Mol Oncol (2012) 1.05
Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype. Mol Cancer Ther (2011) 1.02
PIK3R1 underexpression is an independent prognostic marker in breast cancer. BMC Cancer (2013) 0.99
CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis. Stem Cells (2013) 0.96
Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway. Int J Cancer (2013) 0.93
Multilayered molecular profiling supported the monoclonal origin of metastatic renal cell carcinoma. Int J Cancer (2013) 0.86
Selenate induces epithelial-mesenchymal transition in a colorectal carcinoma cell line by AKT activation. Exp Cell Res (2013) 0.79